The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The impact of rusfertide on PV-related symptoms & patient-reported outcomes in the VERIFY trial
In this video, Alessandro Lucchesi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, briefly discusses the benefits of rusfertide for patients with polycythemia vera (PV) observed in the VERIFY trial (NCT05210790). He highlights patient-reported outcomes and quality of life improvements, particularly reductions in fatigue. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
